Cargando…
Elrexfio™ (elranatamab-bcmm): The game-changer in treatment of multiple myeloma
Multiple myeloma is the second most common plasma cell malignancy, characterized by uncontrolled proliferation of plasma cells within the bone marrow. ELREXFIO™ (elranatamab-bcmm) is a recently FDA-approved drug for relapsed and refractory multiple myeloma. The progression of multiple myeloma involv...
Autores principales: | Rais, Taruba, Khan, Afsheen, Riaz, Rumaisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571667/ https://www.ncbi.nlm.nih.gov/pubmed/37840703 http://dx.doi.org/10.1177/20363613231207483 |
Ejemplares similares
-
Epcoritamab-bysp (Epkinly) – A phenomenal breakthrough in the treatment of diffuse large B-cell lymphoma
por: Riaz, Rumaisa, et al.
Publicado: (2023) -
“A beacon of hope for relapsed multiple myeloma patients: TALVEY™”
por: Khaliq, Nawal, et al.
Publicado: (2023) -
Medical Emergency Team: A Game Changer in the Wards
por: Chandrasegarane, Saranya, et al.
Publicado: (2023) -
Is Omicron the game changer of COVID-19 infection in children?
por: Liang, Qiwei, et al.
Publicado: (2022) -
SDF − a game changer?
por: Remtulla, A.
Publicado: (2020)